Front Runners: TerraForm Power (TERP), Virgin America (VA), Abengoa SA (ABGB), Gilead Sciences (GILD)

TerraForm Power, Inc. (TERP) is seeing a big move Tuesday, as the company’s shares surged by over 30% on the day on news that the company together with SunEdison, Inc. (SUNE) have signed a definitive agreement to acquire First Wind, one of the leading developers, owners and operators of wind projects in the U.S.

TerraForm said the transaction is immediately accretive to the company and is expected to deliver $72.5 million in unlevered cash available for distribution (“CAFD”) in fiscal 2015.

TerraForm Power, Inc., currently valued at $1.03B, has a median Wall Street price target of $35.00 with a high target of $37.00. Approximately 1.90M shares have already changed hands, compared to the stock’s average daily volume of 536.83K.

In the past 12 months, shares of Beltsville, Maryland-based company have traded between a low of $21.58 and a high of $34.74 with the 50-day MA and 200-day MA located at $26.80 and $29.35 levels, respectively. Additionally, shares of TERP have a Relative Strength Index (RSI) and MACD indicator of 74.03 and +0.97, respectively.

TERP currently prints a year-to-date gain of around 2%.

Virgin America Inc. (VA) shares are up nearly 14% to $37.25 in mid-day trading. The move comes on a big volume too with the issue currently trading more than 9.7M shares, compared to the average volume of 5.63M shares.

Virgin America is a Beltsville, Maryland-based operator of solar generation assets serving utility. Its stock has a 52-week trading range of $30.00 to $39.64.

The T-12 profit margin at Virgin America is 4.76%. VA‘s revenue for the same period is $1.48B.

Virgin America Inc. has market cap of $1.43B.

Abengoa SA (ABGB) is trading higher by nearly 30% in late trade. Not seeing any news or rumors to account for the move.

Abengoa is a Seville, Spain-based engineering and clean technology company. Its stock has a median consensus analyst price target of $28.72 with a high target of $44.00, and 52-week trading range of $7.71 to $30.75.

The T-12 profit margin at Abengoa SA is 1.69%. ABGB‘s revenue for the same period is $9.49B.

Abengoa SA has a market cap of $23.20B.

ABGB recently traded at $14.61, up $3.26.

Shares of Gilead Sciences Inc. (GILD) are up more than 3% on news that the European Commission has granted marketing authorization for Harvoni, the first once-daily single tablet regimen to treat the majority of chronic hepatitis C genotype 1 and 4 infection in adults.

On valuation measures, Gilead Sciences Inc. shares are currently priced at 18.46x this year’s forecasted earnings and 10.45x next year’s earnings. Ticker has a PEG and forward P/E ratio of 0.52 and 10.44, respectively. Price/sales for the same period is 7.32, while EPS is $5.61. Currently there are 19 analysts that rate GILD a ‘Buy’ ; 4 rate it a ‘Hold’. No analyst rates it a ‘Sell’. GILD has a median Wall Street price target of $126.50.

In the past 52 weeks, shares of Foster City, California-based pharmaceutical company have traded between a low of $63.50 and a high of $116.83 and are now at $103.63. Shares are up 43.71% year-over-year, and 33.74% year-to-date.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.